BioSpace News Archive

Biotech Bay

FibroGen Announces Non-Dilutive Term Loan Financing for up to $150 Million with Morgan Stanley Tactical Value

FibroGen, Inc. (NASDAQ: FGEN) today announced a non-dilutive term loan facility with investment funds managed by Morgan Stanley Tactical Value (MSTV) that will result in proceeds to FibroGen of up to $150 million, bringing significant non-dilutive capital to support growth and innovation.

May 1, 2023
·
4 min read
Bio NC

RedHill’s RHB-102 (BEKINDA®) and Opaganib Granted New Patents in Oncology Setting

RedHill Biopharma Ltd. (NASDAQ: RDHL) (“RedHill” or the “Company”), a specialty biopharmaceutical company, today announced the granting of two new EU and U.S. patents for RHB-102 (BEKINDA)1 and opaganib2, respectively, in the oncology setting.

May 1, 2023
·
10 min read
Biotech Beach

PreludeDx™ Presents Comparative Data at the Annual ASBrS Meeting Analyzing Racial/Ethnic Radiation Therapy Treatment Recommendation Changes using DCISionRT®

Prelude Corporation today announced new results evaluating the decision impact for radiation therapy (RT) recommendations incorporating the DCISionRT test by race (White vs. Black) in women with ductal carcinoma in situ (DCIS) enrolled in the PREDICT study.

May 1, 2023
·
5 min read
Deals

ACELYRIN, INC. Announces Launch of IPO Roadshow

ACELYRIN, INC. today announced it has launched a roadshow for an initial public offering (IPO) of 20,600,000 shares of its common stock.

May 1, 2023
·
2 min read
Business

Compugen to Release First Quarter 2023 Results on Monday, May 15, 2023

Compugen Ltd. today announced that the Company will release its first quarter 2023 financial results on Monday, May 15, 2023, before the U.S. financial markets open.

May 1, 2023
·
2 min read
Business

Syndax to Announce First Quarter 2023 Financial Results and Host Conference Call and Webcast on May 8, 2023

Syndax Pharmaceuticals, Inc. today announced that it will report its first quarter 2023 financial results and provide a business update on Monday, May 8, after the close of the U.S. financial markets.

May 1, 2023
·
1 min read
Drug Development

Zambon Completes Enrollment in Phase 3 Clinical Development Program Evaluating Liposomal Cyclosporine A for Inhalation (L-CsA-i) in Patients with Bronchiolitis Obliterans Syndrome (BOS)

Zambon announced today that the Company has completed enrollment in its two pivotal Phase 3 studies.

May 1, 2023
·
5 min read
BioForest

CTI BioPharma Announces Two Abstracts Accepted for Presentation at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting

CTI BioPharma Corp. today announced that two abstracts have been accepted for presentation at the upcoming 2023 American Society of Clinical Oncology (ASCO) Annual Meeting taking place June 2-6, 2023 in Chicago, IL.

May 1, 2023
·
2 min read
Pharm Country

U.S. FDA Accepts for Priority Review Supplemental Biologics License Application and EMA Validates Application for Reblozyl® (luspatercept-aamt) as First-Line Treatment of Anemia in Adults with Lower-Risk Myelodysplastic Syndromes (MDS)

U.S. FDA Accepts for Priority Review Supplemental Biologics License Application and EMA Validates Application for Reblozyl ® (luspatercept-aamt) as First-Line Treatment of Anemia in Adults with Lower-Risk Myelodysplastic Syndromes (MDS).

May 1, 2023
·
13 min read
Drug Development

Silence Therapeutics Completes Enrollment in Phase 2 Study of Zerlasiran (SLN360) in Subjects with Elevated Lipoprotein(a) at High Risk of Atherosclerotic Cardiovascular Disease Events

Silence Therapeutics plc today announced that it has completed enrollment in the ALPACAR-360 phase 2 study of zerlasiran (SLN360) in subjects with elevated lipoprotein(a) (“Lp(a)”) at high risk of atherosclerotic cardiovascular disease (“ASCVD”) events.

May 1, 2023
·
4 min read